Janssen Biotech gets rights to Genmab's Phase I/II HuMax-CD38
Johnson & Johnson’s Janssen Biotech Inc. has licensed exclusive global development and marketing rights to antibody company Genmab AS’s HuMax-CD38 (daratumumab), which is in Phase I/II for relapsed refractory multiple myeloma, plus a back-up anti-CD38 compound.
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.